FindTrial
Sign In

Allopurinol and Quality of Life in Liver Cirrhosis

the Impact of Allopurinol of HRQOL in Cirrhotic Patients

Status
Completed
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05828836
Enrollment
100
Registered
2023-04-25
Start date
2022-06-15
Completion date
2023-03-01
Last updated
2023-10-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cirrhosis, Liver

Brief summary

The study aims to evaluate the impact of allopurinol on patients' related quality of life.

Detailed description

Cirrhosis is the late stage of liver damage and possess two phases:. The shift from compensated to decompensated cirrhosis is characterized by the onset of complications) which are associated with substantial morbidity and negative Impact on quality of life (QOL)Cirrhosis and its complications have a substantial economic, social, and personal impact on affected patients, as well as their families and caregivers

Interventions

DRUGAllopurinol Tablet

allopurinol300mg once daily

DRUGPlacebo

placebo once daily

Sponsors

Tanta University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

cirrhosis adult both sex

Exclusion criteria

* renal insufficiency

Design outcomes

Primary

MeasureTime frameDescription
Chronic liver disease questionnaire6 monthseffect on Chronic liver disease questionnaire score

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026